Core

<div class="textg" style="text-align: justify; font-weight: lighter; line-height: 1.3em; font-size: 15px; border-radius: 3px; color: #80909a; padding: 10px; background-color: #F4F6F9; margin-bottom: 15px;">
 Neither the author, Tim Fries, nor this website, The Tokenist, provide financial advice. Please consult our&nbsp;<a href="https://tokenist.com/terms-of-service/" style="text-decoration:underline;color:#3c7b7b" target="_blank" rel="noopener noreferrer nofollow" class="deco-link">website policy</a>&nbsp;prior to making financial decisions.
</div>
<p class="has-drop-cap">Danaher Corporation (NYSE: DHR) has reported its <a href="https://investors.danaher.com/2024-07-23-Danaher-Reports-Second-Quarter-2024-Results" target="_blank" aria-label="financial results for the second quarter of 2024 (opens in a new tab)" rel="noopener noreferrer nofollow" class="deco-link">financial results for the second quarter of 2024</a>, showcasing a solid performance despite a slight decline in revenues.</p>
<p>The company announced net earnings of $907 million, or $1.22 per diluted share, with non-GAAP adjusted diluted net earnings per share (<a href="https://tokenist.com/investing/how-to-value-a-stock/" rel="noopener noreferrer nofollow" class="deco-link">EPS</a>) standing at $1.72. <br><br>Revenues for the quarter totaled $5.7 billion, representing a 3.0% year-over-year decrease, while non-GAAP core revenue saw a 3.5% decline. Operating cash flow was reported at $1.4 billion, with non-GAAP free cash flow at $1.1 billion. <br><br>Rainer M. Blair, President and CEO, highlighted the company’s strong execution, particularly in the bioprocessing business and Cepheid, which showed robust performance and market share gains in molecular testing.</p>
<p>Blair expressed optimism about Danaher’s future, emphasizing the company’s transformation into a focused life sciences and diagnostics leader. This transformation, according to Blair, positions Danaher for higher long-term growth, expanded margins, and stronger cash flow.</p>
<h3 id="danaher-corporation-beats-eps-and-revenue-expectations-in-q2">Danaher Corporation Beats EPS and Revenue Expectations in Q2</h3>
<p>When comparing Danaher’s current performance against expectations, the company exceeded the anticipated EPS of $1.57 by delivering a non-GAAP adjusted EPS of $1.72. <br><br>This outperformance underscores Danaher’s ability to navigate challenging market conditions and deliver value to its shareholders. The company’s revenue of $5.7 billion also surpassed the expected $5.59 billion, despite a 3.0% year-over-year decline. <br><br>This better-than-expected revenue performance can be attributed to the sustained positive momentum in the bioprocessing business and strong performance at Cepheid.</p>
<p>The reported operating cash flow of $1.4 billion and free cash flow of $1.1 billion also show Danaher’s strong financial health and its capacity to generate substantial cash flow, which is crucial for funding future growth initiatives and returning value to shareholders.</p>
<div class="cta-referral"><img src="https://tokenist.com/wp-content/themes/thetokenist/assets/img/del/cta-referral-1.png" alt="" class="cta-referral__img" loading="lazy" decoding="async">
 <div class="cta-referral__text">
  <p>Join our&nbsp;<a href="https://t.me/thetokenist" target="_blank" rel="noopener noreferrer nofollow" class="deco-link">Telegram group&nbsp;and never miss a breaking story.</a></p>
 </div>
</div>
<h3 id="danaher-corporation-expects-non-gaap-core-revenue-to-be-down-year-over-year-for-third-quarter-and-the-full-year">Danaher Corporation Expects non-GAAP Core Revenue to Be Down Year-Over-Year for Third Quarter and the Full Year</h3>
<p>Danaher has provided guidance for the third quarter and full year 2024. The company anticipates that non-GAAP core revenue will be down by low-single digits year-over-year for both the third quarter and the full year. <br><br>This cautious outlook reflects the ongoing uncertainties in the global market and the potential impact of various external factors on the company’s operations. Despite the anticipated decline, Danaher remains confident in its long-term growth prospects and strategic positioning.</p>
<p>The company’s guidance underscores its commitment to transparency and prudent financial management. By providing a realistic outlook, Danaher aims to set clear expectations for its stakeholders and navigate the evolving market landscape effectively. <br><br>The focus on non-GAAP core revenue highlights the company’s emphasis on underlying business performance, excluding the impact of currency translation, acquisitions, and divested product lines, which can obscure the true growth trends.</p> <iframe src="https://tokenist.substack.com/embed" width="100%" height="320" style="border:1px solid #EEE; background:white;" frameborder="0" scrolling="no"></iframe>
<p><em>Disclaimer: The author does not hold or have a position in any securities discussed in the article.</em></p>
<h3 id="br"><br></h3>
<p>The post <a rel="noopener noreferrer nofollow" href="https://tokenist.com/danaher-corporation-beats-q2-expectations-with-907-m-in-net-earnings/">Danaher Corporation Beats Q2 Expectations with $907 M in Net Earnings</a> appeared first on <a rel="noopener noreferrer nofollow" href="https://tokenist.com">Tokenist</a>.</p>

Danaher Corporation Beats Q2 Expectations with $907 M in Net Earnings

Table of Contents

Tokenist

Other articles published on Jul 23, 2024

$4M in Bitcoin Seized from Dark Web To Be Sold by US Govt, Will It Impact Price?

2nd Report Of July 2024 - Matrix AI Network

Top 10 Cryptos Trade in Red Zone: Will Solana (SOL) Price Reverse the Trend & Reclaim $180?

This English Football Club is Making a Bold Bet on Bitcoin!

WLD Price Slips 7% Ahead Of Massive Token Unlock

Highly Awaited Spot Ethereum ETFs Officially Launched! How much ETH is in the wallet of the issui...

Join our free newsletter for daily crypto updates!